Post-earnings recap
Reported
Thu, Feb 28, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Nektar Therapeutics reported a wider-than-expected loss per share, which surprised investors positively, but the lack of revenue data and guidance contributed to a slight decline in stock price. The stock fell by 1.19% as investors reacted to the overall uncertainty surrounding future performance. Management's defensive tone may indicate challenges ahead, but they remain focused on long-term goals.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.57 | N/A | +13.28% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook, emphasizing their commitment to long-term objectives. They acknowledged the challenges faced in the current quarter.
Management did not provide specific revenue guidance for the upcoming quarters.
The company remains focused on its long-term strategic goals despite the current financial performance.